JNJ-9375凝血酶抗体与阿哌沙班预防静脉血栓的随机2期试验
这项双盲双模拟2期试验纳入308例膝关节置换术患者,比较术后单次静脉输注JNJ-9375(0.3–1.8 mg/kg)与阿哌沙班(2.5 mg每日两次)的疗效与安全性。JNJ-9375安全但不优于阿哌沙班。
要点
- JNJ-9375抗凝血酶外位点1,抑制底物结合但不影响催化活性。
- JNJ-9375组静脉血栓栓塞发生率31.1%,高于阿哌沙班组的12.2%。
- 两组均无大出血,出血率在最高与最低JNJ-9375剂量间相似。
核心结论
- JNJ-9375安全但疗效低于阿哌沙班,静脉血栓栓塞事件更多。
- JNJ-9375的疗效不足可能反映凝血酶抑制较弱或无法阻止给药前已形成血栓的生长。
研究设计与样本
- 双盲、双模拟2期随机试验,308例膝关节置换术患者随机接受术后单次静脉JNJ-9375(0.3–1.8 mg/kg)或阿哌沙班(2.5 mg每日两次)。
- 主要疗效终点为静脉血栓栓塞发生率,通过强制性单侧静脉造影或确诊的症状性事件评估。
- 主要安全终点为大出血、临床相关非大出血和轻微出血的复合终点。
主要发现
- 改良意向治疗分析纳入239/308例(77.6%),其中238例有可评估静脉造影,1例经超声确诊症状性深静脉血栓。
- JNJ-9375各剂量组事件增多一致,未见更高剂量疗效改善。
- JNJ-9375和阿哌沙班均无大出血,最高与最低JNJ-9375剂量组任何出血率相似。
临床怎么用
- 对于膝关节置换术后静脉血栓预防,JNJ-9375当前证据不支持替代阿哌沙班。
局限性
- 样本量较小,改良意向治疗分析仅纳入239例。
- 疗效比较采用双侧80%置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: JNJ-9375 is an antibody against exosite 1 on thrombin, inhibits substrate binding but not catalytic activity. OBJECTIVE: To examine the possibility that JNJ-9375 attenuates thrombosis without affecting hemostasis, we compared the efficacy and safety of JNJ-9375 and apixaban. METHODS: In this double-blind, double-dummy phase 2 trial, 308 patients undergoing knee arthroplasty were randomized to receive either a single postoperative intravenous infusion of JNJ-9375 in doses ranging from 0.3 to 1.8 mg/kg or apixaban (2.5 mg twice daily). The primary efficacy endpoint was the incidence of venous thromboembolism (assessed by mandatory unilateral venography or confirmed symptomatic events). The primary safety outcome was the composite of major, clinically relevant nonmajor, and minimal bleeding. Thrombin times were measured to assess JNJ-9375 activity. RESULTS: A total of 239 of the 308 patients (77.6%) were included in the modified intention-to-treat analysis. Of these, 238 had evaluable venograms and one had symptomatic deep-vein thrombosis confirmed by ultrasound. Despite dose-dependent thrombin time prolongation, the primary efficacy outcome occurred in 59 of 190 patients (31.1%) in the combined JNJ-9375 groups as compared with 6 of 49 patients (12.2%) given apixaban (odds ratio 3.2; two-sided 80% confidence interval 1.8-5.8; P = .011). The excess events with JNJ-9375 compared with apixaban were consistent across all JNJ-9375 dosing cohorts and there was no evidence of improved efficacy with higher JNJ-9375 doses. There were no major bleeds with JNJ-9375 or apixaban, and rates of any bleeding were similar with the highest and lowest JNJ-9375 doses. CONCLUSIONS: JNJ-9375 was safe but less effective than apixaban. This may reflect weak thrombin inhibition or inability of JNJ-9375 to attenuate the growth of thrombi that formed before drug administration.
引用
- Weitz JI, Segers A, Raskob G, et al. Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. J Thromb Haemost. 2019. PMID: 31529590. doi:10.1111/jth.14639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。